PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 256 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 2.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $5,984,000 | +1.6% | 85,376 | -13.2% | 0.01% | 0.0% |
| Q4 2020 | $5,889,000 | +2.6% | 98,411 | +3.1% | 0.01% | 0.0% |
| Q3 2020 | $5,739,000 | +19.6% | 95,457 | +4.4% | 0.01% | 0.0% |
| Q2 2020 | $4,798,000 | +56.8% | 91,449 | +0.2% | 0.01% | +25.0% |
| Q1 2020 | $3,060,000 | -60.0% | 91,249 | -45.9% | 0.00% | -42.9% |
| Q4 2019 | $7,646,000 | +139.4% | 168,778 | +101.2% | 0.01% | +133.3% |
| Q3 2019 | $3,194,000 | +41.1% | 83,905 | +61.1% | 0.00% | 0.0% |
| Q2 2019 | $2,264,000 | +14.1% | 52,067 | -0.2% | 0.00% | +50.0% |
| Q1 2019 | $1,985,000 | -12.7% | 52,151 | -1.3% | 0.00% | -33.3% |
| Q4 2018 | $2,274,000 | -8.4% | 52,851 | +4.7% | 0.00% | 0.0% |
| Q3 2018 | $2,482,000 | +42.9% | 50,500 | -6.8% | 0.00% | +50.0% |
| Q2 2018 | $1,737,000 | -14.2% | 54,200 | -16.6% | 0.00% | -33.3% |
| Q1 2018 | $2,025,000 | -34.9% | 65,000 | -4.6% | 0.00% | -25.0% |
| Q4 2017 | $3,109,000 | +25.6% | 68,100 | +3.3% | 0.00% | 0.0% |
| Q3 2017 | $2,475,000 | -19.8% | 65,900 | +1.9% | 0.00% | -20.0% |
| Q2 2017 | $3,086,000 | +6.9% | 64,700 | +2.2% | 0.01% | 0.0% |
| Q1 2017 | $2,886,000 | +35.2% | 63,300 | -4.2% | 0.01% | +25.0% |
| Q4 2016 | $2,135,000 | -5.6% | 66,100 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $2,262,000 | -5.2% | 66,100 | -6.5% | 0.00% | 0.0% |
| Q2 2016 | $2,385,000 | -38.2% | 70,700 | -3.0% | 0.00% | -33.3% |
| Q1 2016 | $3,862,000 | -35.0% | 72,900 | -5.8% | 0.01% | -33.3% |
| Q4 2015 | $5,944,000 | +427.9% | 77,400 | +182.5% | 0.01% | +350.0% |
| Q3 2015 | $1,126,000 | -65.6% | 27,400 | -40.8% | 0.00% | -60.0% |
| Q2 2015 | $3,274,000 | -31.5% | 46,300 | +3.2% | 0.01% | -28.6% |
| Q1 2015 | $4,778,000 | 0.0% | 44,873 | 0.0% | 0.01% | 0.0% |
| Q4 2014 | $4,778,000 | +15.3% | 44,873 | +4.9% | 0.01% | +16.7% |
| Q3 2014 | $4,144,000 | +33.9% | 42,760 | +26.9% | 0.01% | +50.0% |
| Q2 2014 | $3,096,000 | +103.1% | 33,705 | +44.7% | 0.00% | +100.0% |
| Q1 2014 | $1,524,000 | +2527.6% | 23,300 | +1841.7% | 0.00% | – |
| Q3 2013 | $58,000 | +152.2% | 1,200 | +50.0% | 0.00% | – |
| Q2 2013 | $23,000 | – | 800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |